Article
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Nature communications - 13 Jan 2021
Gromeier Matthias, Brown Michael C, Zhang Gao, Lin Xiang, Chen Yeqing, Wei Zhi, Beaubier Nike, Yan Hai, He Yiping, Desjardins Annick, Herndon James E, Varn Frederick S, Verhaak Roel G, Zhao Junfei, Bolognesi Dani P, Friedman Allan H, Friedman Henry S, McSherry Frances, Muscat Andrea M, Lipp Eric S, Nair Smita K, Khasraw Mustafa, Peters Katherine B, Randazzo Dina, Sampson John H, McLendon Roger E, Bigner Darell D, Ashley David M
Abstract excerpt
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associated with longer survival after recombinant polio virotherapy or after immune...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.